A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER".
Détails
ID Serval
serval:BIB_D4A7BE0C1D9D
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
A RESPONSE TO "THE POTENTIAL LONG-TERM COMPARATIVE EFFECTIVENESS OF LAROTRECTINIB AND ENTRECTINIB FOR SECOND-LINE TREATMENT OF TRK FUSION-POSITIVE METASTATIC LUNG CANCER".
Périodique
Journal of managed care & specialty pharmacy
ISSN
2376-1032 (Electronic)
ISSN-L
2376-0540
Statut éditorial
Publié
Date de publication
12/2020
Peer-reviewed
Oui
Volume
26
Numéro
12
Pages
1616-1617
Langue
anglais
Notes
Publication types: Letter ; Comment
Publication Status: ppublish
Publication Status: ppublish
Résumé
DISCLOSURES: The writing of this letter was sponsored by Roche/Genentech. All authors are employees of, and hold stocks in, F. Hoffmann-La Roche Ltd/Genentech Inc.
Mots-clé
Benzamides, Humans, Indazoles, Lung Neoplasms, Protein Kinase Inhibitors, Pyrazoles, Pyrimidines
Pubmed
Web of science
Open Access
Oui
Création de la notice
03/07/2023 16:12
Dernière modification de la notice
04/07/2023 5:55
Données d'usage
